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A comparative study between plasma diagnostic markers and oxidative stress-induced biomarkers local-
ized differently in liver has not been reported in non-




Pathological observations by Hematoxylin and Eosin (HE) staining and immunostaining by specific antibodies against metallothionein (MT)-1/2 and -3,
heme oxygenase-1(HO-1),adiponectin using biopsy samples and plasma diagnostic makers were deter-
mined in 37 cases.
Results
 
The MT-1/2,HO-1 and adiponectin levels were all significantly reduced in the liver with NASH compared with NAFLD and control. MT-1/2 was most strongly stained in hepatocytes in the normal and NAFLD liver, while it was significantly reduced in NASH. Adiponectin was stained significantly less at
 




The significantly reduced expression of oxidative stress-induced biomarkers in NASH may be associated with the degree of pathological damage. In particular,
MT-1/2 seemed to play the important role in he-
patocytes against stress-induced damage in NASH.
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